Reuters logo
BRIEF-Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine
April 24, 2017 / 8:45 PM / 5 months ago

BRIEF-Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine

April 24 (Reuters) - Amgen Inc:

* Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine

* Says co, Novartis agreed to combine capabilities to co-commercialize erenumab in U.S.; Amgen retains exclusive commercialization rights in Japan

* Says Novartis gains exclusive rights to commercialize erenumab in Canada, retains existing commercialization rights in rest of the world

* Says co will receive milestone payments from Novartis expected to begin in 2017; Novartis will share u.s. Commercialization costs with Amgen

* Says co will book sales of erenumab in the U.S., and will pay a royalty to Novartis on net sales in the u.s.

* Says Novartis to book sales in rest of the world (excluding Japan), to pay co royalties on net sales in those countries; co to book sales in Japan

* Says Novartis will assume agreed upon remaining global development costs up to a cap and share global development costs thereafter Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below